



Testing Neurofilament Light (NF-L) chain in blood samples to monitor neurodegenerative diseases and support clinical drug development.



Victor Ayala, PhD, an early stage investigator with ABL, discusses how to accelerate vaccine production using a nonviral enabling technology for cell engineering.



GMP manufacturing services for your oncolytic, vaccine and gene therapy projects in all phases of clinical development & upon product approval.

ABL Europeu2019s (Strasbourg site) Certificate of GMP Compliance related to 2016 facility inspection for: Quality Control Testing.

[Download](#)

ABL Europeu2019s (Strasbourg site) Certificate of GMP Compliance related to 2016 facility inspection for: Human Investigational Medicinal Products: Aseptic Filling, Gene Therapy Product Manufacturing, and Secondary Packaging.

[Download](#)

ABL Lyon's site is accredited for ISO 9001.

ABL's U.S. location is accredited for Good Clinical Laboratory Practices (GCLP) standards.

ABL's U.S. location is accredited for ISO 9001.

The EQAP0L ELISpot EQA program assesses the proficiency of NIAID/DAIDS-supported and other interested research laboratories at performing an interferon- γ (IFN- γ) ELISpot assay.

[Download](#)

Revolutionary treatments require innovative analytics. ABL's immunologists have decades of experience developing immunoassays for challenging vaccine and therapeutic products.